ABL1 and acute lymphoblastic leukemia: To evaluate if BCL2 and BCR-ABL1 inhibition was effective against Ph+ B-ALL cells, we exposed them to Nilotinib, Venetoclax or their combination, measuring both proliferation and cell death (Figure 5).